Statements (52)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:pharmaceuticals
|
gptkbp:administered_by |
subcutaneous injection
|
gptkbp:administered_every |
6 months
|
gptkbp:approves |
gptkb:FDA
|
gptkbp:clinical_trial |
gptkb:ARCH_trial
gptkb:FREEDOM_trial gptkb:REPLACE_trial Phase 3 DATA trial FREEDOM Extension trial |
gptkbp:clinical_use |
treatment of osteoporosis
treatment of bone loss associated with hormone ablation |
gptkbp:contraindication |
pregnancy
lactation hypersensitivity to denosumab hypocalcemia |
gptkbp:dosage_form |
injection
|
gptkbp:excretion |
via the reticuloendothelial system
|
gptkbp:formulation |
solution for injection
|
https://www.w3.org/2000/01/rdf-schema#label |
Prolia
|
gptkbp:indication |
prevention of bone fractures
|
gptkbp:ingredients |
gptkb:denosumab
|
gptkbp:interacts_with |
other medications affecting calcium levels
|
gptkbp:is_monitored_by |
bone mineral density
calcium levels |
gptkbp:lifespan |
about 26 days
|
gptkbp:long_term_use |
safety and efficacy established
|
gptkbp:manufacturer |
gptkb:Amgen
|
gptkbp:marketed_as |
gptkb:2010
|
gptkbp:mechanism_of_action |
RANKL inhibitor
|
gptkbp:packaging |
single-use prefilled syringe
|
gptkbp:patient_education |
importance of calcium and vitamin D
importance of regular dental check-ups signs of infection to report |
gptkbp:patient_population |
postmenopausal women
men at high risk for fracture |
gptkbp:pharmacokinetics |
subcutaneous absorption
|
gptkbp:price |
varies by region and insurance
|
gptkbp:regulatory_compliance |
approved in multiple countries
|
gptkbp:requires |
available from manufacturer
|
gptkbp:route_of_administration |
subcutaneous
|
gptkbp:safety_features |
generally well tolerated
|
gptkbp:side_effect |
injection site reactions
skin rash osteonecrosis of the jaw hypocalcemia atypical femoral fractures |
gptkbp:storage |
refrigerated
|
gptkbp:trade |
gptkb:denosumab
|
gptkbp:used_for |
osteoporosis
|
gptkbp:bfsParent |
gptkb:Amgen
|
gptkbp:bfsLayer |
4
|